Image source: The Motley Fool. Wednesday, Feb. 11, 2026 at 8 a.m. ET Call participants Chief Scientific Officer — Gary Barnett, M.D. Chief Financial Officer and Chief Administrative Officer — Michele Greco General Counsel — Phil Greenberg Executive Director of Investor Relations and Corporate Communications — Sam Fisch Chief Executive Officer — Mitchell Steiner, M.D. Need a quote from a Motley Foo...
Image source: The Motley Fool. Wednesday, Feb. 11, 2026 at 8 a.m. ET Call participants Chief Scientific Officer — Gary Barnett, M.D. Chief Financial Officer and Chief Administrative Officer — Michele Greco General Counsel — Phil Greenberg Executive Director of Investor Relations and Corporate Communications — Sam Fisch Chief Executive Officer — Mitchell Steiner, M.D. Need a quote from a Motley Fool analyst? Email [email protected] Takeaways Public offering proceeds -- $23,400,000 raised through an underwritten public offering, increasing liquidity significantly for upcoming operations. -- $23,400,000 raised through an underwritten public offering, increasing liquidity significantly for upcoming operations. Cash position -- $33,000,000 in cash, cash equivalents, and restricted cash at quarter-end, a rise from $15,800,000 as of Sept. 30, 2025. -- $33,000,000 in cash, cash equivalents, and restricted cash at quarter-end, a rise from $15,800,000 as of Sept. 30, 2025. Net working capital -- $29,700,000 at quarter-end, up from $11,100,000 in the preceding quarter. -- $29,700,000 at quarter-end, up from $11,100,000 in the preceding quarter. Net loss -- $5,300,000, or $0.26 per diluted share, down from $8,900,000, or $0.61 per share, in the prior-year period. The prior period included a net loss of $7,100,000 from discontinued operations. -- $5,300,000, or $0.26 per diluted share, down from $8,900,000, or $0.61 per share, in the prior-year period. The prior period included a net loss of $7,100,000 from discontinued operations. Research and development expense -- Decreased to $1,300,000 from $5,700,000 due to the wind-down of the Novosarm Phase 2b quality clinical study. -- Decreased to $1,300,000 from $5,700,000 due to the wind-down of the Novosarm Phase 2b quality clinical study. General and administrative expense -- $4,100,000, a decrease from $5,200,000 sequentially from the prior quarter, reflecting reduced share-based compensation. -- $4,100,000, a decrease from $5,200...